Condition: Metastatic Breast Cancer · Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Sponsor: Boehringer Ingelheim
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (T-DXd), with trastuzumab emtansine (T-DM1), with trastuzumab and capecitabine, with zanidatamab, or with mFOLFOX6 (with or without trastuzumab). Another purpose is to check whether zongertinib alone and in combination with other treatments can make tumours shrink. Zongertinib inhibits HER2. HER2 causes cancer cells to grow. In this study, participants receive treatment in cycles. Study participants are treated with zongertinib alone or in combination with other treatments. This study has 2 parts. In Part 1, participants in different groups receive increasing doses of zongertinib. In Part 2, participants are put into different groups by chance. Each group receives a different dose of zongertinib. Every participant has an equal chance of being in each group. During the study, the participants visit the study site regularly. In this study, researchers want to find the highest dose of zongertinib that participants can tolerate when taken together with other treatments. To find this out, researchers look at certain severe health p…
This description comes directly from the study's public registry record.
Boehringer Ingelheim · 1-800-243-0127 · clintriage.rdg@boehringer-ingelheim.com
Always discuss trial participation with your own doctor first.
| The Oncology Institute of Hope and Innovation | Cerritos, California, United States | Recruiting |
| Ellison Medical Institute | Los Angeles, California, United States | Not Yet Recruiting |
| Valkyrie Clinical Trials | Los Angeles, California, United States | Recruiting |
| University of California Los Angeles | Los Angeles, California, United States | Not Yet Recruiting |
| University of California Irvine | Orange, California, United States | Recruiting |
| Sharp Memorial Hospital | San Diego, California, United States | Not Yet Recruiting |
| Yale University School of Medicine | New Haven, Connecticut, United States | Recruiting |
| Helios CR Inc | Lakeland, Florida, United States | Recruiting |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa, Florida, United States | Not Yet Recruiting |
| Orchard Healthcare Research Inc.- Skokie | Skokie, Illinois, United States | Not Yet Recruiting |
| Community Health Network | Indianapolis, Indiana, United States | Not Yet Recruiting |
| University of Iowa Hospitals and Clinics | Iowa City, Iowa, United States | Recruiting |
+ 93 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06324357